Annovis Bio has published phase 3 Parkinson’s disease data, reporting success in subgroups and secondary endpoints

Annovis Bio released its delayed phase 3 Parkinson's disease trial data, highlighting success in specific subgroups and secondary endpoints without clearly addressing the primary goal. The trial involved 523 early Parkinson's patients to assess if six months of daily buntanetap improved MDS-UPDRS scores compared to placebo. The company emphasized cognitive improvements with the higher buntanetap dose, though cognition wasn't a listed secondary endpoint. Annovis focused on subpopulations due to challenges in assessing overall efficacy, noting significant MDS-UPDRS improvements in patients diagnosed over three years ago and those with postural instability and gait difficulty. The data release followed delays due to data cleaning efforts.